Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VitaliThy: Efgartigimod PH20 SC in Graves' Disease
NCT07596849Phase 3Recruiting
- Sponsor
- argenx
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Antibody Fragments, Therapeutic Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of efgartigimod alfa + hyaluronidase-qvfc in Graves' disease (5 arms), sponsored by argenx. Primary endpoint: Percentage of participants who are euthyroid off ATDs at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT07596849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596849.